Hodgkin Lymphoma Drug Pipeline Analysis Report 2025
Description
Hodgkin lymphoma (HL) is a rare cancer of the lymphatic system, affecting lymph nodes and compromising immune function. Globally, it accounts for 0.4% of newly reported cancer cases and 0.2% of cancer-related deaths. The Hodgkin lymphoma drug pipeline is expanding due to the rising demand for advanced therapies and personalized treatments. There is a growing focus on immunotherapies and targeted drugs to improve patient outcomes. Recent developments include Innovent Biologics' IBI322, a recombinant anti-CD47/PD-L1 bispecific antibody, which showed a 47.8% objective response rate in a Phase I trial for patients resistant to anti-PD-(L)1 therapies. Such emerging treatments promise enhanced efficacy, offering hope for improved survival rates and quality of life.
Report Coverage
The Hodgkin Lymphoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into Hodgkin lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Hodgkin Lymphoma. The Hodgkin lymphoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Hodgkin lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Hodgkin lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Hodgkin lymphoma.
Hodgkin Lymphoma Drug Pipeline Outlook
Hodgkin lymphoma is a type of cancer that affects the lymphatic system, which is a vital part of the body's immune system. It occurs when abnormal lymphocytes, a kind of white blood cell, grow uncontrollably. This can lead to symptoms such as swollen lymph nodes, fatigue, and night sweats. The exact cause of Hodgkin lymphoma is still unclear, but factors like genetic mutations and viral infections, particularly the Epstein-Barr virus (EBV), may increase the risk.
Hodgkin lymphoma treatments typically include chemotherapy, radiation therapy, and immunotherapy. Emerging targeted therapies are proving to be effective options for advanced cases. Early-stage Hodgkin lymphoma often responds well to a combination of chemotherapy and radiation. For patients with relapsed or refractory Hodgkin lymphoma, options such as stem cell transplants and new immunotherapies, including checkpoint inhibitors, show promising outcomes and improved survival rates.
Hodgkin Lymphoma Epidemiology
Globally, Hodgkin lymphoma accounted for 0.4% of newly reported cancer cases and 0.2% of cancer-related deaths in 2020. In the United States, approximately 8,720 new cases and 1,150 deaths are projected for 2025. The United Kingdom reports around 2,200 new cases annually, while India sees approximately 1,000 cases each year. The Hodgkin lymphoma drug pipeline is expanding, focusing on advanced therapies and improved patient outcomes.
Hodgkin Lymphoma – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of Hodgkin lymphoma drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total Hodgkin lymphoma clinical trials.
Hodgkin Lymphoma – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the Hodgkin lymphoma pipeline analysis include monoclonal antibodies, antibody-drug conjugates, small molecules, cellular therapies, immunomodulators, and others. The Hodgkin lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Hodgkin lymphoma.
Hodgkin Lymphoma Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the Hodgkin lymphoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Hodgkin lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Hodgkin lymphoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Hodgkin lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Hodgkin lymphoma drug candidates.
Drug: Brentuximab Vedotin with Doxorubicin, Vinblastine and Dacarbazine
Brentuximab Vedotin is an antibody-drug conjugate targeting the CD30 antigen on Hodgkin Reed–Sternberg cells. It is a part of a Phase IV study, sponsored by Takeda, which aims to evaluate the safety and efficacy of Brentuximab Vedotin combined with doxorubicin, vinblastine, and dacarbazine (AVD) in adults with untreated Stage 3/4 classical Hodgkin lymphoma.
Drug: Tislelizumab
Tislelizumab is a humanized IgG4 monoclonal antibody developed by BeiGene. It is currently being evaluated in a Phase III study for relapsed or refractory classical Hodgkin lymphoma (cHL). This trial aims to assess its efficacy by measuring Progression-Free Survival (PFS). Tislelizumab blocks PD-1 interactions, with engineered features to enhance antitumor activity and reduce macrophage-related resistance.
Drug: CD30.CAR-T
CD30.CAR-T, sponsored by Tessa Therapeutics, is being evaluated in the Phase II CHARIOT study for patients with relapsed or refractory Hodgkin lymphoma. This therapy uses genetically modified T cells to target CD30+ cancer cells. The study aims to assess safety, tolerability, and efficacy, with primary completion expected by May 2025.
Reasons To Buy This Report
The Hodgkin Lymphoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Hodgkin lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Hodgkin lymphoma collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Hodgkin Lymphoma – Pipeline Insight Report
Global Hodgkin’s Lymphoma Treatment Market Report and Forecast
Global Non-Hodgkin’s Lymphoma Treatment Market Report and Forecast
Global Clinical Trials Market
Report Coverage
The Hodgkin Lymphoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into Hodgkin lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Hodgkin Lymphoma. The Hodgkin lymphoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Hodgkin lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Hodgkin lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Hodgkin lymphoma.
Hodgkin Lymphoma Drug Pipeline Outlook
Hodgkin lymphoma is a type of cancer that affects the lymphatic system, which is a vital part of the body's immune system. It occurs when abnormal lymphocytes, a kind of white blood cell, grow uncontrollably. This can lead to symptoms such as swollen lymph nodes, fatigue, and night sweats. The exact cause of Hodgkin lymphoma is still unclear, but factors like genetic mutations and viral infections, particularly the Epstein-Barr virus (EBV), may increase the risk.
Hodgkin lymphoma treatments typically include chemotherapy, radiation therapy, and immunotherapy. Emerging targeted therapies are proving to be effective options for advanced cases. Early-stage Hodgkin lymphoma often responds well to a combination of chemotherapy and radiation. For patients with relapsed or refractory Hodgkin lymphoma, options such as stem cell transplants and new immunotherapies, including checkpoint inhibitors, show promising outcomes and improved survival rates.
Hodgkin Lymphoma Epidemiology
Globally, Hodgkin lymphoma accounted for 0.4% of newly reported cancer cases and 0.2% of cancer-related deaths in 2020. In the United States, approximately 8,720 new cases and 1,150 deaths are projected for 2025. The United Kingdom reports around 2,200 new cases annually, while India sees approximately 1,000 cases each year. The Hodgkin lymphoma drug pipeline is expanding, focusing on advanced therapies and improved patient outcomes.
Hodgkin Lymphoma – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of Hodgkin lymphoma drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Monoclonal Antibodies
- Antibody-Drug Conjugates
- Small Molecules
- Cellular Therapies
- Immunomodulators
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total Hodgkin lymphoma clinical trials.
Hodgkin Lymphoma – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the Hodgkin lymphoma pipeline analysis include monoclonal antibodies, antibody-drug conjugates, small molecules, cellular therapies, immunomodulators, and others. The Hodgkin lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Hodgkin lymphoma.
Hodgkin Lymphoma Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the Hodgkin lymphoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Hodgkin lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Hodgkin lymphoma clinical trials:
- Takeda
- AstraZeneca
- Merck Sharp & Dohme LLC
- Tessa Therapeutics
- Akeso
- Guangzhou Gloria Biosciences Co., Ltd.
- Immune Cell, Inc.
- Bristol-Myers Squibb
- Teva Pharmaceuticals
- Seagen Inc.
- Incyte Corporation
- Pfizer
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Hodgkin lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Hodgkin lymphoma drug candidates.
Drug: Brentuximab Vedotin with Doxorubicin, Vinblastine and Dacarbazine
Brentuximab Vedotin is an antibody-drug conjugate targeting the CD30 antigen on Hodgkin Reed–Sternberg cells. It is a part of a Phase IV study, sponsored by Takeda, which aims to evaluate the safety and efficacy of Brentuximab Vedotin combined with doxorubicin, vinblastine, and dacarbazine (AVD) in adults with untreated Stage 3/4 classical Hodgkin lymphoma.
Drug: Tislelizumab
Tislelizumab is a humanized IgG4 monoclonal antibody developed by BeiGene. It is currently being evaluated in a Phase III study for relapsed or refractory classical Hodgkin lymphoma (cHL). This trial aims to assess its efficacy by measuring Progression-Free Survival (PFS). Tislelizumab blocks PD-1 interactions, with engineered features to enhance antitumor activity and reduce macrophage-related resistance.
Drug: CD30.CAR-T
CD30.CAR-T, sponsored by Tessa Therapeutics, is being evaluated in the Phase II CHARIOT study for patients with relapsed or refractory Hodgkin lymphoma. This therapy uses genetically modified T cells to target CD30+ cancer cells. The study aims to assess safety, tolerability, and efficacy, with primary completion expected by May 2025.
Reasons To Buy This Report
The Hodgkin Lymphoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Hodgkin lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Hodgkin lymphoma collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Hodgkin Lymphoma – Pipeline Insight Report
- Which companies/institutions are leading the Hodgkin lymphoma drug development?
- What is the efficacy and safety profile of Hodgkin lymphoma pipeline drugs?
- Which company is leading the Hodgkin lymphoma pipeline development activities?
- What is the current Hodgkin lymphoma commercial assessment?
- What are the opportunities and challenges present in the Hodgkin lymphoma drug pipeline landscape?
- What is the efficacy and safety profile of Hodgkin lymphoma pipeline drugs?
- Which company is conducting major trials for Hodgkin lymphoma drugs?
- Which companies/institutions are involved in Hodgkin lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in Hodgkin lymphoma?
Global Hodgkin’s Lymphoma Treatment Market Report and Forecast
Global Non-Hodgkin’s Lymphoma Treatment Market Report and Forecast
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Hodgkin Lymphoma
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Hodgkin Lymphoma
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Hodgkin Lymphoma: Epidemiology Snapshot
- 5.1 Hodgkin Lymphoma Incidence by Key Markets
- 5.2 Hodgkin Lymphoma – Patients Seeking Treatment in Key Markets
- 6 Hodgkin Lymphoma: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Hodgkin Lymphoma: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Hodgkin Lymphoma, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Hodgkin Lymphoma Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Hodgkin Lymphoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Brentuximab Vedotin with Doxorubicin, Vinblastine and Dacarbazine
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Tislelizumab
- 10.2.3 Drug: Pembrolizumab with Brentuximab Vedotin
- 10.2.4 Other Drugs
- 11 Hodgkin Lymphoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: CD30.CAR-T
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: AZD3470
- 11.2.3 Other Drugs
- 12 Hodgkin Lymphoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Biological: ICAR30 T cells
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Hodgkin Lymphoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Hodgkin Lymphoma, Key Drug Pipeline Companies
- 14.1 Takeda
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 AstraZeneca
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Merck Sharp & Dohme LLC
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Tessa Therapeutics
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Akeso
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Guangzhou Gloria Biosciences Co., Ltd.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Immune Cell, Inc.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Bristol-Myers Squibb
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Teva Pharmaceuticals
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Seagen Inc.
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 14.11 Incyte Corporation
- 14.11.1 Company Snapshot
- 14.11.2 Pipeline Product Portfolio
- 14.11.3 Financial Analysis
- 14.11.4 Recent News and Developments
- 14.12 Pfizer
- 14.12.1 Company Snapshot
- 14.12.2 Pipeline Product Portfolio
- 14.12.3 Financial Analysis
- 14.12.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
